FiftyBidsGovernment contracts and grants, in one plain-English search.

Back to search

Forecast

Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy.

FromNational Institutes of Health
Who can applystate governments, counties, cities and townships, special districts (water, fire, parks, etc.), school districts, public colleges and universities and 9 more types
Eligibility notesOther Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S.
How muchAmount not stated
DeadlineWed, Nov 11, 2026 (estimated) (19 days left)
CategoryHealth
TypeGrant
Opportunity #PAR-26-152
Assistance listing93.395
PostedTue, Mar 3, 2026

Heads-up: Forecast: not open yet. Dates and amounts are the agency's estimates.

Open the official posting

From the notice

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments. Early synthetic lethality–based therapeutic strategies in oncology primarily focused on targeting fixed mutations or genomic abnormalities. More recently, however, it has become clear that clinical benefit is often determined by context-dependent vulnerabilities arising from the intrinsic mutational landscape and adaptive tumor responses.This NOFO is unique in its scope, supporting innovative cancer therapy strategies that explicitly exploit context-dependent effects of radiation therapy (RT) using drug-radiation combinations. The central premise of the PAIRS is that these conditional RT-induced responses can be leveraged to create or enhance actionable vulnerabilities that synergize with molecularly targeted agents for better outcomes. A defining feature of PAIRS is its emphasis on precision, scientific rigor, and reproducibility, aligned with NIH’s scientific priorities. Radiation effects are clinically titratable through advances in delivery accuracy and flexibility, in

We may have shortened this. The official posting is the record. We are not affiliated with the agency that published it.